Showing 3051-3060 of 3844 results for "".
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- Tapinarof Sustains AD Remission for 75+ Days Post-Treatmenthttps://practicaldermatology.com/news/tapinarof-sustains-ad-remission-for-75-days-post-treatment/2484253/New long-term data from the ADORING 3 trial show that tapinarof cream 1% (VTAMA, Organon), a non-steroidal topical aryl hydrocarbon receptor agonist, can sustain low disease activity and pruritus in patients with atopic dermatitis (AD), including children as young
- Deucravacitinib Provides Superior Real-World PsO Skin Clearance at 6 Monthshttps://practicaldermatology.com/news/deucravacitinib-provides-superior-real-world-pso-skin-clearance-at-6-months/2484117/Real-world data from the North American cohort of the RePhlect registry confirm that deucravacitinib provides significantly better skin clearance than apremilast at 6 months in adults with moderate-to-severe plaque psoriasis.
- Nemolizumab Shows Durable Patient-Reported Benefits at 100 Weeks in PNhttps://practicaldermatology.com/news/nemolizumab-shows-durable-patient-reported-benefits-at-100-weeks-in-pn/2484116/Long-term treatment with nemolizumab continues to deliver clinically meaningful improvements in itch, sleep, and quality of life for patients with prurigo nodularis (PN), according to interim results from the open-label extension (OLYMPIA-LTE) study presented by Dr
- Dr. Darrell Rigel Highlights Advances in Skin Cancer Carehttps://practicaldermatology.com/news/dr-darrell-rigel-highlights-advances-in-skin-cancer-care/2484095/Darrell S. Rigel, MD, MS, provided a comprehensive update on the rapidly evolving landscape of skin cancer diagnosis, treatment, and prognostication at the 2025 Fall Clinical Dermatology Conference. From novel genetic assays to refinements in field therapy and systemic strategies, Dr. Rigel’s tal
- ICONIC-TOTAL: Icotrokinra Shows Skin Clearance in Difficult-to-Treat PsO at 1 Yearhttps://practicaldermatology.com/news/iconic-total-icotrokinra-shows-skin-clearance-in-difficult-to-treat-pso-at-1-year/2484061/Icotrokinra, a novel oral IL-23 inhibitor, was associated with imporvements in plaque psoriasis in difficult-to-treat areas of the body, according to new data presented at 2025 Fall Clinical Dermatology Conference in Las Vegas.
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- Latino Melanoma Patients Face Barriers to Early Diagnosis and Treatmenthttps://practicaldermatology.com/news/latino-melanoma-patients-face-barriers-to-early-diagnosis-and-treatment/2483846/A new qualitative study published in JAMA Dermatology explored persistent disparities Latino patients face in timely melanoma diagnosis and treatment, despite advances in therapy that have improved survival among non-Hispani
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- IFPA Highlights Patient Voices in Global Health Policy at UN Panelhttps://practicaldermatology.com/news/ifpa-highlights-patient-voices-in-global-health-policy/2483540/The International Federation of Psoriatic Disease Associations (IFPA) issued a call to global policymakers to recognize psoriatic disease as a serious noncommunicable disease (NCD) with system-wide implications at the 80th UN General Assembly in New York.